Group Health Cooperative of Puget Sound


Group Health Cooperative is a consumer-governed, nonprofit health care system that coordinates care and coverage. Based in Seattle, Group Health and Group Health Options, Inc. serve more than 540,000 members in Washington and Idaho. Its Center for Health Studies has been able to study Group Health's member population over time. Center researchers have access to decades of high-quality, computerized data from the Group Health system. They also have access to information regarding diagnoses and medical history that's stored in non-computerized medical charts. The Center's medical record reviewers abstract data from 15,000 outpatient charts each year. To date, records-based studies with active Group Health members have achieved retrieval for 95 percent of all subjects. Information concerning the ability of outside researchers to use information in the Cooperative's databases was not available on the website.

Selected References


Buist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L. Hormone therapy prescribing patterns in the United StatesExternal Web Site Policy. Obstet Gynecol. 2004 Nov;104(5 Pt 1):1042-50.


Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control studyExternal Web Site Policy. Cancer. 2004 Jun 1;100(11):2308-16.

Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancerExternal Web Site Policy. JAMA. 2004 Feb 18;291(7):827-35.

Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancerExternal Web Site Policy. JAMA. 2002 Feb 13;287(6):734-41.

Rossing MA, Scholes D, Cushing-Haugen KL, Voigt LF. Cimetidine use and risk of prostate and breast cancerExternal Web Site Policy. Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):319-23.

Cost/Cost Effectiveness

Hershman D, Sundararajan V, Jacobson JS, Heitjan DF, Neugut AI, Grann VR. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysisExternal Web Site Policy. J Clin Oncol. 2002 Jan 1;20(1):9-16.

Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer careExternal Web Site Policy. J Natl Cancer Inst. 1995 Mar 15;87(6):417-26.

Fishman P, Taplin S, Meyer D, Barlow W. Cost-effectiveness of strategies to enhance mammography useExternal Web Site Policy. Eff Clin Pract. 2000 Sep-Oct;3(5):213-20.

Return to Top